CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia
- 1 September 2009
- journal article
- Published by Elsevier in Leukemia Research
- Vol. 33 (9) , 1212-1216
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- The cut‐off levels of CD23 expression in the differential diagnosis of MCL and CLLHematological Oncology, 2008
- CD200: A putative therapeutic target in cancerBiochemical and Biophysical Research Communications, 2008
- Rationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: new concepts in blocking immune suppressionExpert Opinion on Biological Therapy, 2007
- Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeuticsNature Reviews Cancer, 2007
- Lack of Extracellular Signal-Regulated Kinase Mitogen-Activated Protein Kinase Signaling Shows a New Type of MelanomaCancer Research, 2007
- CD200 as a prognostic factor in acute myeloid leukaemiaLeukemia, 2007
- Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profilingBlood, 2005
- Rabbit Monoclonal AntibodiesAmerican Journal of Clinical Pathology, 2005
- CD23 Expression in Mantle Cell Lymphoma: Clinicopathologic Features of 18 CasesAmerican Journal of Clinical Pathology, 2003
- Value of CD23 Determination by Flow Cytometry in Differentiating Mantle Cell Lymphoma From Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaAmerican Journal of Clinical Pathology, 2001